- Home
- UTHR vs ASTS Comparison
UTHR vs ASTS Comparison
Compare UTHR & ASTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTHR
- ASTS
- Stock Information
- Founded
- UTHR 1996
- ASTS 2019
- Country
- UTHR United States
- ASTS United States
- Employees
- UTHR N/A
- ASTS N/A
- Industry
- UTHR Biotechnology: Pharmaceutical Preparations
- ASTS Telecommunications Equipment
- Sector
- UTHR Health Care
- ASTS Consumer Discretionary
- Exchange
- UTHR Nasdaq
- ASTS Nasdaq
- Market Cap
- UTHR 13.8B
- ASTS 13.6B
- IPO Year
- UTHR 1999
- ASTS N/A
- Fundamental
- Price
- UTHR $405.02
- ASTS $38.72
- Analyst Decision
- UTHR Strong Buy
- ASTS Buy
- Analyst Count
- UTHR 15
- ASTS 7
- Target Price
- UTHR $449.13
- ASTS $42.98
- AVG Volume (30 Days)
- UTHR 902.7K
- ASTS 8.9M
- Earning Date
- UTHR 10-29-2025
- ASTS 11-13-2025
- Dividend Yield
- UTHR N/A
- ASTS N/A
- EPS Growth
- UTHR 17.94
- ASTS N/A
- EPS
- UTHR 25.63
- ASTS N/A
- Revenue
- UTHR $3,077,800,000.00
- ASTS $4,892,000.00
- Revenue This Year
- UTHR $13.89
- ASTS $1,259.55
- Revenue Next Year
- UTHR $5.68
- ASTS $352.79
- P/E Ratio
- UTHR $15.80
- ASTS N/A
- Revenue Growth
- UTHR 17.62
- ASTS 249.43
- 52 Week Low
- UTHR $266.98
- ASTS $17.50
- 52 Week High
- UTHR $436.95
- ASTS $60.95
- Technical
- Relative Strength Index (RSI)
- UTHR 71.35
- ASTS 33.91
- Support Level
- UTHR $395.00
- ASTS $36.08
- Resistance Level
- UTHR $401.62
- ASTS $50.44
- Average True Range (ATR)
- UTHR 13.35
- ASTS 2.89
- MACD
- UTHR 6.12
- ASTS -0.94
- Stochastic Oscillator
- UTHR 76.31
- ASTS 15.42
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
About ASTS AST SpaceMobile Inc.
AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building a cellular broadband network in space to operate directly with standard, unmodified mobile devices, and off-the-shelf mobile phones based on extensive IP and patent portfolio. It has focused on eliminating the connectivity gaps faced by mobile subscribers. The Company's spaceMobile Service is being designed to provide cost-effective, high-speed Cellular Broadband services to end-users who are out of terrestrial cellular coverage using existing mobile devices.